12:00 AM
 | 
Mar 26, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tenecteplase: Phase IIb data

Researchers at the University of Newcastle and colleagues reported data from the double-blind, Australian Phase IIb TAAIS trial in 75 patients showing that tenecteplase met the co-primary endpoints of greater reperfusion at 24 hours on perfusion-weighted MRI (79.3% vs. 55.4%, p=0.004) and greater clinical improvement at 24 hours as measured by NIHSS scores vs. alteplase (8 vs. 3 points, p<0.001). Additionally, a significantly greater proportion of patients receiving tenecteplase had excellent or good recovery at 90 days as measured by an mRS score of 0-2 (72% vs. 44%,...

Read the full 430 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >